Tag Archives: HIV/AIDS

Experimental HIV Vaccine Shows Promise in Early Human Trial

Above, a red AIDS awareness ribbon.
Image: Shutterstock (Shutterstock)

An experimental HIV vaccine appears to have passed its first test in humans. In a newly released study, the vaccine candidate produced the sort of immune response that scientists had been hoping for in 97% of recipients. Importantly, the vaccine also seemed to be safe and well-tolerated.

The vaccine candidate is known as eOD-GT8 60mer and was developed by researchers from the Scripps Research Institute. The Phase I trial testing eOD-GT8 60mer, first announced in 2018, was sponsored by the International AIDS Vaccine Initiative (IAVI). It’s part of a large collaboration between scientists at Scripps, the National Institutes of Health, the Fred Hutchinson Cancer Center, and other groups in the U.S. and Sweden. It involved 48 healthy participants, 36 of whom were given two doses of the vaccine eight weeks apart (these participants were divided into a low- and high-dose group).

HIV infection can be now effectively managed through lifelong antiviral therapy. But the virus has the ability to craftily change its structure once inside the body, making it hard for the immune system to recognize it for long. This means that sustained immunity to the virus, at least in most cases, has remained out of reach. But we’ve known for decades that some people can produce broadly neutralizing antibodies to the virus that can keep up with it. And scientists have been chasing after the elusive HIV vaccine capable of creating these antibodies ever since.

A new method for obtaining these antibodies, known as the germline-targeting strategy, is represented by eOD-GT8 60mer. In simple terms, the first dose of vaccine tries to prime a rare and select group of B cells into a state where they could produce these antibodies. Subsequent boosters are then supposed to reactivate these cells, eventually leading to durable and broadly neutralizing antibodies against HIV. And in the findings of this new trial, published Friday in Science, the first part of this strategy appears to be working.

The researchers found that 35 out of 36 volunteers appeared to generate the precursors to these broadly neutralizing antibodies and that this immune response only grew in strength following the second dose.

“The hope is that if you can induce this kind of immunity in people, you can protect them from some of these viruses that we’ve had a very hard time designing vaccines for that are effective,” Timothy Schacker, the program director in HIV medicine at the University of Minnesota Medical School, who was not involved in the research, told CNN. “So this is an important step forward.”

Phase I trials are primarily designed to test the safety of an experimental treatment. And the vaccine also did have a favorable safety profile, the researchers wrote, with no severe vaccine-related adverse reactions reported. The findings are timely as well, given that yesterday was World AIDS Day.

This study is only a proof of concept, though, the authors note. It will take more research in humans to confirm the early findings seen here, and to show that broadly neutralizing antibodies can be reliably coaxed through boosters. Any truly effective vaccine would also likely have to create a broad T cell response to HIV since T cells are often a crucial aspect of our immunity to germs. But if this research does continue to pan out, then scientists may one day be able to create vaccines that not only provide lasting protection against HIV, but other evasive diseases like hepatitis C, flu, and covid-19.

Another Phase I trial of eOD-GT8 60mer is already ongoing, and other similar vaccine candidates are being tested out in early human trials as well.

Read original article here

Italian Man With Fever Learns He Has Monkeypox, Covid-19, and HIV All at Once

An example of monkeypox rashes.
Image: Shutterstock (Shutterstock)

A 36-year-old man in Italy appears to be uniquely unlucky, after he was hospitalized and diagnosed with covid-19, monkeypox, and HIV over a span of a single week in July. Thankfully, his covid and monkeypox co-infections did successfully clear up without issue, and he has since been placed on HIV treatment.

His doctors describe this unfortunate medical tale in a case report published last week in the Journal of Infection. According to the report, the man first became ill with a fever, sore throat, and headache on June 29, nine days after having returned from a trip to Spain. On July 2, he tested positive for the SARS-CoV-2 coronavirus, but that same day, he also noticed a rash starting to develop on his left arm. Over the next few days, the rash turned into small, painful blisters that spread along his face, torso, lower limbs, and glutes. On July 5, he sought care at the emergency department of a local hospital in Catania, Italy, where he was then admitted into the infectious disease unit.

Given the man’s symptoms and recent travel to Spain, doctors quickly suspected monkeypox infection and collected samples for testing (the country was one of the first to report cases this year). While in Spain, the man also reported having condomless sex with other men, which has been a risk factor for monkeypox during the current outbreak. Finally, on July 6, the man tested positive for monkeypox, HIV, and the coronavirus—specifically, the Omicron BA.5.1 variant.

“To date, no reports of co-infection with monkeypox virus and SARS-CoV-2 have been published,” the authors wrote. “Therefore, in this study we present the clinical features and diagnostic procedure of the first documented case of co-infection with monkeypox virus, SARS-CoV-2, and HIV-1.”

Due to their respective incubation periods, the man could have caught the coronavirus and monkeypox at the same time. It’s thought to take anywhere from three to 17 days after exposure for monkeypox symptoms to appear, and around two to 14 days for covid-19 symptoms to show up (though the incubation period has likely gotten shorter on average for Omicron). As for the HIV infection, the man told doctors that he tested negative for it in September 2021. And since his CD4 lymphocyte count was still normal, it’s likely that this infection was caught recently as well. It can take 10 to 90 days following exposure to test positive for HIV, depending on the test used, and early flu-like symptoms may appear within a few weeks to a month.

Though co-infections can sometimes contribute to more severe illness, it’s not clear whether that played any role in this case. By day three of the man’s hospitalization, most of his rashes started to crust over; by day five, his symptoms had almost completely resolved and he was sent home soon after. By July 13, he was no longer testing positive for the coronavirus, and on July 19, a follow-up visit to the doctors revealed that his crusty rashes had healed over almost completely, though he was still positive for monkeypox on a swab test. He was also started on a standard combination therapy for HIV, which is known to be very effective at keeping the chronic infection at bay when taken regularly.

While monkeypox may be able to spread to others through any kind of prolonged close contact, evidence continues to show that the vast majority of cases during this outbreak have been transmitted during sex, and most often among gay and bisexual men who have had multiple recent partners—perhaps both from close contact with contagious rashes and through infectious semen or other bodily fluids. Because the covid-19 pandemic is still ongoing and monkeypox cases are on the rise, the authors say that doctors should be aware of the possibility of co-infection in high-risk groups. They also add that their case emphasizes the predominant role that sex could be having in spreading monkeypox.

“Therefore, complete STI screening is recommended after a diagnosis of monkeypox,” they wrote.

Read original article here

Monkeypox patient’s nose is rotting after being dismissed as sunburn

A man’s nose began to rot in one of the most shocking monkeypox cases reported so far.

The 40-year-old German patient went to his doctor after a red spot developed on his nose. It was then assumed to be a sunburn, and the man was sent home.

But within a few more days, the lesion on his nose began to turn black.

The man soon also found pus-filled sores all over his body, which were particularly severe around his penis and mouth, as reported in the medical journal Infection.

The unnamed man was then tested for monkeypox, and given antivirals to combat the virus. While at the hospital he was also tested for various sexually transmitted illnesses — for the first time, he told doctors — which revealed he also had undiagnosed syphilis and HIV.

His syphilis had gone so long undetected that it spread to multiple organs; meanwhile, tests confirmed that his HIV infection had developed into AIDS.

The man’s nose began to rot following a monkeypox diagnosis and undiagnosed STIs.
Boesecke, C., Monin, M.B., van Bremen, K. et al.
The man was given antiviral medication which helped the lesions but did little to help his nose.
MediaNews Group via Getty Images

As for his case of monkeypox, the antiviral medication was enough to dry out the sores on the skin, but only partially improved the nose by reducing swelling.

According to study authors, the man’s case was so severe because the HIV left him immunocompromised and susceptible to necrosis — the death of body tissue.

Doctors who penned the article for Infection did not provide an update on the man’s recovery.

Germany currently has 3,186 cases of monkeypox recorded since May 20, with only the US (12,689) and Spain (5,719) reporting more cases. There are currently just over 38,000 cases worldwide, according to the Center for Disease Control and Prevention.

Monkeypox was declared a public health emergency in the US earlier this month. after it spread across the country following an outbreak in Europe this spring.

Germany has the third highest monkeypox case count in the world.
Getty Images/Science Photo Libra

The virus has primarily spread through gay and bisexual men, who account for about 98% of patients — although women, children and heterosexual men are just as likely to become sick if directly exposed to monkeypox.

Dr. John Whyte, chief medical officer of WebMD, told The Post that doctors “are still learning about it,” but reassured patients of their worst fears. “We haven’t known [the current outbreak] to be fatal. And that’s a good thing,” Whyte said.

This week gay Texan porn star Silver Steele documented his painful monkeypox symptoms after being diagnosed with the virus several weeks ago. Steele photographed the lesions on his chin area as they developed over time — showing they were at their worst at 11 days after they the first spot surfaced. It took more than 3 weeks for the symptoms to completely subside.

Read original article here

FDA approves first condom meant for anal sex

The Food and Drug Administration (FDA) on Wednesday authorized the first-ever condom intended for safe anal intercourse.

Authorization of the One Male Condom is expected to help reduce the transmission of sexually transmitted infections (STIs), including HIV/AIDS in both anal and vaginal intercourse, the FDA said in a press release.

“The risk of STI transmission during anal intercourse is significantly higher than during vaginal intercourse. The FDA’s authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse,” said Courtney Lias, the director of the FDA’s Office of GastroRenal, ObGyn, General Hospital, and Urology Devices in the Center for Devices and Radiological Health.

“Furthermore, this authorization helps us accomplish our priority to advance health equity through the development of safe and effective products that meet the needs of diverse populations,” Lias continued.

The One Male Condom is produced by the Global Protection Corp and is available in dozens of sizes and fits.

Before seeking FDA approval, the company conducted a trial of 252 men who had sex with other men and 252 men who had sex with women. Participants, all aged between 18 and 54, were asked to track sexual activity in a journal.

The results, published in the journal Lancet in 2019, showed failure rates were lower for the One Male Condom during anal intercourse than for vaginal intercourse, according to the FDA.

David Wedel, the president and founder of Global Protection Corp, called the FDA’s approval of the One Male Condom a “landmark shift” in the public health sphere.

“I think most people would be surprised to know that condoms are not approved for anal sex,” he said in a statement. “With this new designation from the FDA, people will have more confidence using condoms for anal sex.”

Aaron Siegler, an associate professor of Epidemiology at the Rollins School of Public Health at Emory University who led the study, said “over 300 condoms approved for use with vaginal sex data, and never before has a condom been approved based on anal sex data.”

“This is despite two-thirds of HIV transmission in the United States being linked to anal sex,” Siegler said in a statement. “Having condoms tested and approved for anal sex will allow users to have confidence in using condoms to prevent HIV transmission.”

During the pandemic, condom sales across the world have fallen.



Read original article here

The First FDA-Authorized Condom for Anal Sex Is Here

Photo: One Condoms

The Food and Drug Administration has authorized the first condom designed specifically for anal sex. The One Male Condom, as it’s being marketed, can be used for vaginal sex as well, but it’s hoped this authorization will improve condom use for anal sex, which carries a higher risk of spreading certain sexually transmitted infections like HIV.

The One Male Condom was tested out in a clinical trial of just over 500 people, with two groups split evenly between men who have sex with men and men who have sex with women. The failure rate of the condom—defined as the condom slipping off or breaking during sex—was found to be 0.68% during anal sex, and 1.92% during vaginal sex. There were no serious adverse events reported, though less than 1% of participants did report an STI or recent STI diagnosis during the trial. Though these infections may reflect the rare risk of condom failure, it’s also possible that some cases preceded the trial or could have occurred in the absence of condom use.

Condoms and similar barrier methods have long been recommended for all forms of sexual intercourse, anal included, to prevent the spread of sexually transmitted infections. And every FDA-cleared condom, including this one, can still be used to prevent STIs and pregnancy from vaginal sex, the FDA notes. But authorizing the One Male Condom, the agency said, may encourage more people to wear a rubber during anal sex when they wouldn’t otherwise—an important goal, given its added infection transmission risks. It’s also possible, the FDA added, that this authorization will pave the way for similar products to get to market faster.

The FDA’s authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse,” said Courtney Lias, director of the FDA’s Office of GastroRenal, ObGyn, General Hospital, and Urology Devices in the Center for Devices and Radiological Health, in an FDA statement. “Furthermore, this authorization helps us accomplish our priority to advance health equity through the development of safe and effective products that meet the needs of diverse populations.”

The One Male Condom, made out of natural rubber latex, is being marketed under Global Protection Corp’s One condom brand. It will come in three varieties, standard, thin, and fitted, with the fitted version coming in 54 sizes. When used for anal sex, it should be paired with a condom-safe lubricant. And though this and other condoms may work just fine for any type of intercourse, the CDC still recommends that people use a fresh condom when switching between anal, oral, and vaginal sex.

Read original article here

A New, Long-Acting HIV Prevention Drug Just Got FDA Approval

Photo: Sean Gallup (Getty Images)

The Food and Drug Administration has approved a new form of pre-exposure prophylaxis (PrEP) for preventing cases of HIV. The treatment is called Apretude, and it’s the first PrEP medication to be taken via injection instead as a once-daily pill. Apretude will only need to be taken once a month initially, then every two months, likely providing a more convenient option for many people.

The first PrEP treatment, Truvada, was approved by the FDA in 2012. In 2019, Descovy became the second PrEP treatment to be approved. Both were developed by Gilead Sciences and rely on a two-drug combination of existing antivirals commonly used to treat HIV. When taken as prescribed, PrEP is highly effective at preventing sexually transmitted HIV infections (around 99% effective), though it’s less effective (74%) at preventing infection contracted from sharing contaminated needles.

The growing use of PrEP has likely contributed to declining rates of new HIV infections seen recently in the U.S., but its implementation has run into stumbles. The brand-name drugs have been relatively expensive, costing over $1,500 per month without insurance. Until recently, even PrEP users with insurance still often faced high out-of-pocket costs. And it’s only this year, following lengthy resistance by Gilead, that other drug manufacturers were allowed to widely produce a generic equivalent to Truvada, which has led to a sharp price drop for the treatment.

Outside of cost, the once-daily dosage for PrEP presented a challenge, since many people eligible for the treatment may not be able or willing to maintain their regimen. So Apretude may provide more opportunities for PrEP to be used.

The drug is an extended-release injectable suspension of the HIV antiviral cabotegravir, developed by ViiV Healthcare. It’s been approved for teens and adults who are considered to be at higher risk for contracting HIV-1, the primary subtype of the virus in the U.S. People starting on Apretude will take it once a month for the first two months, and then every two months afterward. Those considering Apretude can also first take the oral version of cabotegravir for a month, to assess its tolerability.

“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” said Debra Birnkrant, director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research, in the FDA’s announcement of the approval. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option.”

Though Apretude may represent an important step forward for HIV prevention, it will not come cheaply. The list price of the drug is expected to run around $3,700 per dose, according to NBC News. Over a year’s time on a six-dose schedule, the drug will cost around $22,000 a year, or roughly the same amount that Truvada did yearly. Starting this year, however, many health coverage plans will be required to pay the entire costs of PrEP, without any out-of-pocket costs for users. But high list prices can still limit the availability and affordability of a drug, particularly for uninsured people.

Read original article here

Biden scorns Trump, Bush on World AIDS Day despite GOP presidents’ efforts

WASHINGTON — President Biden on Wednesday knocked his predecessor Donald Trump in a World AIDS Day speech and claimed House Speaker Nancy Pelosi got “even” President George W. Bush to care about HIV/AIDS.

Biden jabbed at Trump despite the former president setting a 2030 goal to end HIV transmission and seemed to also minimize Bush’s leadership in creating the PEPFAR program that saved millions of lives and reduced HIV infections by giving medicine to poor and mostly African countries.

“Nancy, not a joke, you were the one who started that fight in a way that you took it on with such passion,” Biden told Pelosi (D-Calif.) at the White House. “It was viewed as a political death sentence to take this issue on at the time. But you did it. You fundamentally changed the way we looked at this. You even got George Bush to lead on this too.”

President Joe Biden listens during an event to commemorate World AIDS Day in the East Room of the White House on Dec. 1, 2021.
Stefani Reynolds / CNP / SplashN

Working in a dig at Trump, though not by name, Biden put on a look of disgust while delivering the applause line: “When my administration came to office, not only did we re-establish the White House Office of National AIDS policy which hard to believe…”

“That was the easiest possible thing to do,” Biden continued. “No, I really mean it. Think about it, think about it, it gets a round of applause in the year 2021 when we say that? I mean, it should have never ever — anyway, I don’t want to get into that.”

Biden didn’t mention Trump’s surprising 2019 launch of a federal initiative “to eliminate the HIV epidemic in the United States within 10 years.” Trump backed that plan with a final budget request of $716 million to fight HIV/AIDS.

Dr. Anthony Fauci listens as President Biden delivers remarks to commemorate World AIDS Day at the White House on Dec. 1, 2021.
Anna Moneymaker/Getty Images
Former President Donald Trump and Jerry Falwell. Trump set a goal to end HIV transmission by 2030.
Alex Wong/Getty Images

Biden told the crowd about his administration’s own $670 million HIV/AIDS budget request, which actually is less than Trump’s.

“We’re going to take aggressive action and back it up. We’ve asked Congress for $670 million, a historic budget request, for the ending the HIV epidemic in the United States initiative,” Biden said.

The president gave Bush greater credit later in the event, while regaling the crowd about his own role re-authorizing Bush’s PEPFAR program, which the Republican president proposed in January 2003 before Congress approved an initial $15 billion to aid poor countries. Pelosi was not a bill sponsor, but voted for the bill and supported PEPFAR extensions.

The White House is decorated to commemorate World AIDS Day on Dec. 1, 2021.
AP Photo/Susan Walsh
President Biden seemed to also minimize former President George W. Bush’s role in setting up the PEPFAR program that saved millions of lives.
Matthew Cavanaugh-Pool/Getty images

“Leading reauthorization of PEPFAR in 2008 was among the highlights of my time as chairman of the foreign relations committee,” Biden said. “I was not one of the great leaders in this. I always supported the effort but it was because I was chairman of the committee. And believe it or not, there was a Republican president, and I’m not being a wise guy when I say this, who pushed for PEPFAR.”

Later, Biden noted that Bush, who often cited his Christian faith when pushing PEPFAR and credited Condoleeza Rice with advising him on the matter, founded the ambitious global HIV/AIDS program.

“Since President Bush launched PEPFAR in 2003, we’ve saved more than 21 million lives. we’ve prevented millions of HIV infections and we’ve helped at least 20 countries bring their HIV epidemics under control or reach their… treatment targets,” Biden said.

“Through PEPFAR the United States will support nearly 19 million men, women and children with life-saving HIV treatment. It’s an incredible, incredible achievement.”

Read original article here

Scientists Say a Second HIV Patient Cleared the Virus Naturally

Photo: China Photos (Getty Images)

Researchers in Massachusetts say they’ve discovered a second patient who seems to have completely defeated an HIV infection without the help of antiviral treatments or a bone marrow transplant. The case of the Esperanza patient, as the woman is now being called, suggests that more people can naturally clear the viral infection than currently assumed, according to the authors. It also offers more hope that a similar cure can be found for the vast majority of patients who are burdened with HIV their whole lives.

Members of the Ragon Institute—a medical institute focused on HIV research, with scientists from the Massachusetts General Hospital, the Massachusetts Institute of Technology, and Harvard University—have been studying a particular group of HIV patients for years now. These patients are known as “elite controllers,” and they all appear to have immune systems that can effectively keep HIV in check without antiretroviral therapy (ART), the standard course of treatment.

For most infected people, ART is needed to keep the virus from replicating en masse inside certain immune cells, which eventually destroys the immune system and causes the condition known as AIDS. While ART can sink levels of HIV so low that the person is no longer contagious to others, the virus is still able to hide inside some cells and avoid complete eradication. Usually, if a person stops taking ART (or if the virus evolves enough resistance to the drugs), the virus can emerge from this reservoir and wreak havoc again. Elite controllers, on the other hand, seem to not need treatment at all, keeping their HIV viral load low on their own.

In August 2020, the group published their latest research on elite controllers. One of these patients had not only controlled the infection by herself, they argued, but had eradicated it entirely. The group was unable to find any traces of the virus in more than 1 billion blood cells taken from this patient, even using the latest genetic tests.

There have been other patients documented to have completely or practically beaten HIV. These patients are traditionally given a nickname to preserve their anonymity, usually corresponding to their locale, such as the Berlin patient. Two patients are known to have remained wholly HIV-free—what’s known as a sterilizing cure—after undergoing a bone marrow transplant. Bone marrow transplants effectively replace a person’s immune system with that of a donor’s, and both patients were given bone marrow from individuals with a rare genetic mutation thought to make them much less vulnerable to HIV infection. Though successful, bone marrow transplants are far too dangerous and cumbersome to ever become a mainstay HIV cure. There have also been other cases of people who have had persistently low levels of HIV after they stopped taking ART.

But the group’s San Francisco patient is unique even among these cases, since she never underwent any treatment. At the time, the researchers speculated that this patient may not be the only one to be found among their elite controllers. And they were seemingly right. In a new study published Monday in the Annals of Internal Medicine, they now claim to have documented a second such patient, who they’ve dubbed the Esperanza patient. As before, the group was unable to find any amount of the virus in over 2 billion blood and tissue cells collected from the woman.

“The examples of these two cases really suggest that our current efforts to find a cure for HIV infection are not elusive. If we learn how natural immunity to the virus works, we’re going to be able to do this,” study author Xu Yu, a Ragon Institute researcher, told Gizmodo by phone.

There are still many puzzles to be solved about these cases. The San Francisco patient first contracted HIV in 1992 and has long been studied as an elite controller, but it’s not known when her infection went from being contained to being conquered. The Esperanza patient, on the other hand, had lived with HIV for about seven years before Yu’s group declared her cured, which raises the possibility that a natural victory over the virus may not take so many years for those blessed with the ability to do so. The group believes that more naturally cured people are out there, unaware of their good fortune.

Of course, the most pivotal question is how the immune system of these two individuals has pulled off this trick. Yu’s group and others suspect that certain immune cells programmed to kill other immune cells hijacked by germs like HIV play a key role, but it’s likely that more than one mechanism is involved. Some of the group’s elite controllers also appear to be functionally cured, with the virus contained to parts of a cell’s genome where it can never replicate itself back to full strength.

One priority for Yu’s group is to find more of these elite controllers and naturally cured people to better understand their biology. But many researchers, including Yu and her colleagues, are already working on strategies to help other people based on what we’ve learned from those with built-in hardiness to the virus. These include therapeutic vaccines that can hopefully train the immune system to recognize reservoirs of HIV.

“The next step is going to be: How do we use therapeutic vaccines and other approaches to mimic the responses we’re seeing in these individuals over to the broader patient population?” Yu said. “If we can mimic what we’re seeing from elite controllers, not even necessarily these two patients, we can bring people at least to a kind of functional cure before we’re talking about a sterilizing cure.”

Read original article here